Drug Discoveries and Therapeutics

Scope & Guideline

Shaping the landscape of modern medicine.

Introduction

Explore the comprehensive scope of Drug Discoveries and Therapeutics through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore Drug Discoveries and Therapeutics in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN1881-7831
PublisherINT RESEARCH & COOPERATION ASSOC BIO & SOCIO-SCIENCES ADVANCEMENT
Support Open AccessNo
Country-
TypeJournal
Converge1997, from 2010 to 2018, 2020 (coverage discontinued in Scopus)
AbbreviationDRUG DISCOV THER / Drug Discov. Ther.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressINT RESEARCH & COOPERATION ASSOC BIO & SOCIO-SCIENCES ADVANCEMENT, TOKYO 00000, JAPAN

Aims and Scopes

The journal "Drug Discoveries and Therapeutics" focuses on advancing the fields of drug discovery, development, and therapeutic applications. It encompasses a broad range of research areas, methodologies, and clinical implications, aiming to address contemporary challenges in pharmacology and therapeutics.
  1. Drug Discovery and Development:
    The journal emphasizes innovative approaches in drug discovery, including the exploration of new compounds, mechanisms of action, and therapeutic targets. This includes both traditional and modern methods, such as high-throughput screening and computational drug design.
  2. Pharmacokinetics and Pharmacodynamics:
    Research on the pharmacokinetics (absorption, distribution, metabolism, and excretion) and pharmacodynamics (drug effects and mechanisms) of various therapeutic agents is a core focus, ensuring that new drugs are both effective and safe for patients.
  3. Clinical Applications and Trials:
    The journal publishes studies related to clinical trials and real-world applications of drugs. This includes efficacy and safety evaluations, as well as studies on patient outcomes and quality of life improvements associated with therapeutic interventions.
  4. Traditional and Complementary Medicine:
    There is a notable interest in traditional medicine, particularly Chinese herbal remedies, and their integration into modern therapeutic practices. The journal explores the efficacy, mechanisms, and potential of these treatments in contemporary healthcare.
  5. Emerging Therapeutic Strategies:
    Research on novel therapeutic strategies, including biologics, gene therapy, and nanotechnology for drug delivery systems, is highlighted, showcasing the journal's commitment to innovative treatment modalities.
  6. Antimicrobial Resistance and Infectious Diseases:
    The journal addresses the growing concern of antimicrobial resistance through research on new antimicrobial agents and strategies to combat resistant infections, thus contributing to public health initiatives.
The journal has demonstrated adaptability to emerging trends and themes within the fields of drug discovery and therapeutics. Recent publications reflect a dynamic focus on contemporary challenges and innovative solutions in healthcare.
  1. Digital Health and Telepharmacy:
    There is an increasing emphasis on digital health solutions, including telepharmacy and the use of technology in medication management. This trend is particularly relevant in the context of the COVID-19 pandemic, which has accelerated the adoption of remote healthcare services.
  2. Microbiome Research:
    Research linking the microbiome to drug efficacy and safety is on the rise. Understanding the role of the gut microbiome in drug metabolism and therapeutic outcomes is emerging as a critical area of study, with significant implications for personalized medicine.
  3. COVID-19 Related Research:
    The journal has seen a substantial increase in publications related to COVID-19, focusing on therapeutic interventions, vaccine development, and the long-term impact of the pandemic on health systems and drug discovery.
  4. Nanotechnology in Drug Delivery:
    Nanotechnology is gaining traction as a method for improving drug delivery systems. Research exploring nanoparticles for targeted therapy and enhanced bioavailability is emerging as a significant theme.
  5. Sustainability in Drug Development:
    There is a growing focus on sustainable practices in drug development, including the use of eco-friendly materials and processes. This trend reflects broader societal concerns about environmental impact and the pharmaceutical industry's role in sustainability.

Declining or Waning

While "Drug Discoveries and Therapeutics" continues to explore a wide array of research topics, certain themes have seen a decline in prominence over recent years. This may reflect shifts in research focus or emerging priorities within the field.
  1. Conventional Pharmacotherapy:
    Research centered solely on conventional pharmacotherapy without consideration of novel approaches or complementary therapies appears to be waning. This shift indicates a growing preference for integrated treatment strategies that combine traditional and innovative methods.
  2. Single-Agent Studies:
    There is a noticeable decrease in publications focusing exclusively on the effects of single-agent therapies. The trend is moving towards combination therapies and multi-targeted approaches, reflecting the complexity of diseases and the need for more comprehensive treatment regimens.
  3. Basic Science in Isolation:
    Studies that focus exclusively on basic scientific research without clinical relevance or application are becoming less common. The journal is increasingly prioritizing research that translates basic science into practical therapeutic applications.
  4. Local or Regional Drug Issues:
    Research that addresses drug issues specific to localized or regional contexts, without broader implications or applicability, is declining. There is a shift towards global health perspectives and the implications of drug development on a larger scale.

Similar Journals

International Journal of Pharmacology

Bridging Research and Application in Pharmacology
Publisher: ASIAN NETWORK SCIENTIFIC INFORMATION-ANSINETISSN: 1811-7775Frequency: 8 issues/year

Welcome to the International Journal of Pharmacology, a key publication in the field of pharmacology, published by ASIAN NETWORK SCIENTIFIC INFORMATION (ANSINET). Since its inception in 2006, this journal has provided a vital platform for researchers and professionals to disseminate their findings and insights in pharmacology, toxicology, and pharmaceutics. Despite recent discontinuation in Scopus coverage, the journal's dedication to fostering scientific dialogue continues to attract contributions from esteemed scholars globally. With an **ISSN of 1811-7775** and **E-ISSN of 1812-5700**, the journal seeks to bridge the gap between laboratory research and clinical application, promoting a deeper understanding of drug actions and interactions. Although it operates under traditional access options, the relevance of its published studies to ongoing pharmacological research remains significant.

Drug Research

Transforming Ideas into Therapeutic Realities
Publisher: GEORG THIEME VERLAG KGISSN: 2194-9379Frequency: 9 issues/year

Drug Research, published by GEORG THIEME VERLAG KG, is a pivotal journal housed in the vibrant realm of pharmacology and drug discovery. With a commitment to advancing the understanding of medicinal substances, this journal serves as an essential resource for researchers, professionals, and students dedicated to the field. The journal boasts an ISSN of 2194-9379 and an E-ISSN of 2194-9387, reflecting its dual commitment to print and digital accessibility. Despite its status as a Q3 journal in both Drug Discovery and Miscellaneous Medicine categories as of 2023, it continues to offer valuable insights with a focus on the latest innovations, methodologies, and findings in drug research. Based in Germany, Drug Research promotes scholarly communication and collaboration within the scientific community, ensuring that its contributions remain impactful in shaping future therapeutic discoveries. The journal is indexed in relevant databases, enhancing its visibility and reach, thus fostering a robust academic dialogue.

Drug Target Insights

Advancing the Future of Pharmacology and Drug Discovery.
Publisher: ABOUTSCIENCE SRLISSN: 1177-3928Frequency: 1 issue/year

Drug Target Insights is a prestigious peer-reviewed journal published by ABOUTSCIENCE SRL, catering to the dynamic field of pharmacology and medicinal biochemistry. With an Open Access policy since 2006, the journal aims to promote the dissemination of cutting-edge research and innovations that target drug discovery and therapeutic developments. Based in Milan, Italy, it boasts a notable impact within its research community, achieving a Q3 classification in the categories of Clinical Biochemistry and Medical Pharmacology in 2023, alongside a robust performance in the Q2 category for Pharmacology, Toxicology, and Pharmaceutics. The journal serves as a vital platform for researchers, professionals, and students seeking to advance their understanding of drug delivery systems, therapeutic targets, and pharmacodynamics. With a commitment to enhancing global access to crucial research findings, Drug Target Insights stands out as an essential resource for those engaged in the ever-evolving landscape of pharmaceutical sciences.

TRENDS IN PHARMACOLOGICAL SCIENCES

Pioneering Research for Tomorrow's Pharmacological Challenges
Publisher: CELL PRESSISSN: 0165-6147Frequency: 12 issues/year

TRENDS IN PHARMACOLOGICAL SCIENCES, an esteemed journal published by CELL PRESS, is a leading platform in the field of pharmacology and toxicology, with an impressive history since its inception in 1979. With an impact factor that places it in the top quartile category (Q1) for both pharmacology and toxicology as of 2023, it is recognized for disseminating high-quality, peer-reviewed research that shapes the future of these disciplines. The journal is indexed with a robust standing in Scopus rankings, positioned at rank #2 in Toxicology and #6 in Pharmacology, both boasting an extraordinary percentile of 98. Researchers, professionals, and students benefit from its comprehensive coverage, which spans cutting-edge advancements, review articles, and significant trends in drug development and toxicity assessment. While the journal does not currently offer open access options, it remains a vital resource for the academic community, ensuring critical insights into the complexities of pharmacological sciences are readily available to enhance research and practice.

INVESTIGATIONAL NEW DRUGS

Catalyzing Change in Pharmacological Interventions
Publisher: SPRINGERISSN: 0167-6997Frequency: 6 issues/year

INVESTIGATIONAL NEW DRUGS is a prestigious journal published by SPRINGER, dedicated to advancing research in the fields of pharmacology and oncology. With its origins dating back to 1983, the journal continues to play a critical role in disseminating groundbreaking studies and innovative methodologies related to drug development and therapeutic strategies. It holds an impressive impact factor among leading academic publications, ranking in the top quartiles (Q1 and Q2) of its respective categories, evidenced by Scopus rankings of #43/272 in Medical Pharmacology and #88/404 in Medical Oncology. While it offers traditional subscription-based access, it remains an essential resource for researchers, professionals, and students eager to stay abreast of significant advancements in drug research. Through rigorous peer review and comprehensive coverage, INVESTIGATIONAL NEW DRUGS aims to foster the development of effective new therapies and enhance our understanding of pharmacological interventions in oncology.

CLINICAL PHARMACOLOGY & THERAPEUTICS

Pioneering insights in drug therapy and treatment strategies.
Publisher: WILEYISSN: 0009-9236Frequency: 6 issues/year

CLINICAL PHARMACOLOGY & THERAPEUTICS, published by WILEY, stands at the forefront of pharmacological research, serving as a pivotal resource for researchers, healthcare professionals, and students in the medical field. With its prestigious Q1 rating in both Pharmacology and Pharmacology (medical) categories, and ranking in the top 4% of journals in the field, it provides cutting-edge insights into drug therapy, pharmacokinetics, and innovative treatment strategies. The journal features a wide range of articles, from original research to comprehensive reviews, all aimed at advancing knowledge and clinical practice in pharmacology. With a publication history dating back to 1960 and continuing through 2024, its commitment to excellence is evident in its robust impact factor and high visibility in the academic community. For professionals striving to stay at the forefront of pharmacological advancements, CLINICAL PHARMACOLOGY & THERAPEUTICS remains an essential platform for disseminating and accessing vital research findings.

Drug Design Development and Therapy

Transforming Pharmaceutical Science with Cutting-Edge Insights
Publisher: DOVE MEDICAL PRESS LTDISSN: 1177-8881Frequency: 1 issue/year

Drug Design Development and Therapy is a premier open-access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the fields of drug discovery, pharmaceutical science, and pharmacology. With an impressive Q1 ranking in its categories as of 2023, this journal is recognized for its significant contributions to the understanding of drug design and therapeutic innovations, making it an invaluable resource for researchers, professionals, and students alike. Established in 2007 and committed to open-access since 2008, the journal provides an inclusive platform for disseminating high-quality research from around the globe. With a robust impact factor and remarkable Scopus rankings, including a 24th place in Pharmaceutical Science and a 48th place in Pharmacology, it reflects a strong percentile performance, ensuring that published articles reach and impact a wide audience. By fostering the exchange of cutting-edge information on drug development and delivery systems, Drug Design Development and Therapy continues to play a crucial role in the ongoing battle against disease, promoting innovative approaches to therapeutic solutions and enhancing patient care.

DRUGS

Catalyzing Progress in Pharmacology and Medicine
Publisher: ADIS INT LTDISSN: 0012-6667Frequency: 18 issues/year

DRUGS is a prestigious, peer-reviewed journal published by ADIS INT LTD, specializing in the field of pharmacology across diverse medical applications. With an impressive impact factor and ranking as Q1 in the Pharmacology (Medical) category as per the 2023 metrics, this journal consistently exhibits a strong influence in the medical research community, holding a notable rank of #3 out of 272 in its domain on Scopus, placing it within the 99th percentile. Established in 1971 and converging its insightful contributions until 2024, DRUGS encompasses a broad scope, focusing on the latest advancements in drug research, development, and clinical applications, aiming to bridge the gap between laboratory discoveries and therapeutic practices. Though not an Open Access journal, it remains a key resource for researchers, professionals, and students keen on exploring cutting-edge findings and developments in pharmacology. Its location in the United Kingdom further emphasizes its role as a global leader in pharmaceutical sciences.

FUNDAMENTAL & CLINICAL PHARMACOLOGY

Pioneering insights in pharmacology since 1987.
Publisher: WILEYISSN: 0767-3981Frequency: 6 issues/year

FUNDAMENTAL & CLINICAL PHARMACOLOGY is a distinguished journal dedicated to advancing the fields of pharmacology and clinical medicine. Published by WILEY, this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike to disseminate innovative research findings and clinical applications. With an impressive history spanning from 1987 to 2024, it has consistently maintained its relevance in the scientific community, evidenced by its Q2 quartile ranking in both Pharmacology and Pharmacology (medical) categories for 2023. The journal's diverse publication range, which includes original research articles, reviews, and clinical studies, helps bridge the gap between fundamental research and practical application in healthcare settings. Although it does not offer open access, its rigorous peer-review process ensures that published content meets the highest scholarly standards, making it a vital resource for those aiming to stay at the forefront of pharmacological sciences.

CURRENT PHARMACEUTICAL DESIGN

Leading the Charge in Pharmaceutical Innovations
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1381-6128Frequency: 46 issues/year

CURRENT PHARMACEUTICAL DESIGN is a leading journal in the fields of Drug Discovery and Pharmacology, published by Bentham Science Publishers Ltd in the dynamic United Arab Emirates. With an impressive historical span from 1995 to 2024, this journal serves as a vital platform for disseminating innovative research findings, breakthrough methodologies, and critical reviews that shape the future of pharmaceutical sciences. Ranked Q2 in both Drug Discovery and Pharmacology categories according to the 2023 metrics, it places itself within the top-tier percentile, catering to a diverse audience of researchers, industry professionals, and students. The journal’s commitment to high-quality research exploration is evidenced by its Scopus ranking, where it is positioned favorably within its category ranks. Although currently not Open Access, CURRENT PHARMACEUTICAL DESIGN remains an essential resource for those looking to stay at the forefront of pharmacological advancements and drug development strategies.